Fibroblast growth factor 21 analogues in the FDA pipeline: Hope for metabolic dysfunction-associated steatotic liver disease therapy after resmetirom

Hepatobiliary and Pancreatic Diseases International · Published 2026-07-01 · DOI 10.1016/j.hbpd.2026.07.007

Authors (2)

Somasundaram Sanjay, Devaraj Ezhilarasan

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year
2026

Citation

Sanjay, S., Ezhilarasan, D. (2026). Fibroblast growth factor 21 analogues in the FDA pipeline: Hope for metabolic dysfunction-associated steatotic liver disease therapy after resmetirom. Hepatobiliary and Pancreatic Diseases International. https://doi.org/10.1016/j.hbpd.2026.07.007

Related articles